Market Place
Sourcing Support
PolyPid Corporate Update & Reports Q3 2024 Financial Results
13 Nov 2024 //
GLOBENEWSWIRE
PolyPid to Attend Craig-Hallum Alpha Select Conference
07 Nov 2024 //
GLOBENEWSWIRE
PolyPid to Report Q3 2024 Results on Nov 13, 2024
30 Oct 2024 //
GLOBENEWSWIRE
PolyPid Publishes Phase 3 SHIELD I Trial Results In Surgery Journal
21 Oct 2024 //
GLOBENEWSWIRE
PolyPid Completes Last Patient In for SHIELD II Interim Analysis
01 Oct 2024 //
GLOBENEWSWIRE
PolyPid to Participate in Three Upcoming Fall Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
PolyPid Provides Corporate Update And Reports Q2 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
01 Aug 2024 //
GLOBENEWSWIRE
PolyPid To Report Q2 2024 Results On August 14
31 Jul 2024 //
GLOBENEWSWIRE
PolyPid Hosts KOL Call On Unmet Need In SHIELD II Trial Update
18 Jun 2024 //
GLOBENEWSWIRE
PolyPid Hosts KOL Event, Updates On D-PLEX100 Phase 3 Trial
10 Jun 2024 //
GLOBENEWSWIRE
PolyPid Q1 2024 Update, Financial Results
08 May 2024 //
GLOBENEWSWIRE
PolyPid to Participate in Citizens JMP Life Sciences Conference
01 May 2024 //
GLOBENEWSWIRE
PolyPid Enrolls 200th Patient in SHIELD II Ph3 for D-PLEX™
30 Apr 2024 //
GLOBENEWSWIRE
PolyPid Reports Q1 2024 Highlights on May 8
24 Apr 2024 //
GLOBENEWSWIRE
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
28 Feb 2024 //
GLOBENEWSWIRE
PolyPid Announces Enrollment of the 100th Patient in the SHIELD II Phase 3 Trial
12 Feb 2024 //
GLOBENEWSWIRE
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
04 Jan 2024 //
GLOBENEWSWIRE
PolyPid Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
PolyPid Announces Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
07 Nov 2023 //
GLOBENEWSWIRE
PolyPid to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
11 Oct 2023 //
GLOBENEWSWIRE
PolyPid Announces Presentation at the American College of Surgeons Congress
09 Oct 2023 //
GLOBENEWSWIRE
PolyPid Announces Publication of Data Further Supporting Technology Platform
04 Oct 2023 //
GLOBENEWSWIRE
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
22 Sep 2023 //
GLOBENEWSWIRE
PolyPid Announces Successful Commercial GMP Audit by Israeli Ministry of Health
21 Sep 2023 //
GLOBENEWSWIRE
PolyPid Announces Reverse Share Split
20 Sep 2023 //
GLOBENEWSWIRE
PolyPid Announces Successful Completion of Manufacturing Process Validation
19 Sep 2023 //
GLOBENEWSWIRE
PolyPid Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
PolyPid to Report Second Quarter 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
PolyPid Announces New Publication Highlighting Potent Antibacterial of D-PLEX
29 Jun 2023 //
GLOBENEWSWIRE
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq
05 Jun 2023 //
GLOBENEWSWIRE
PolyPid Announces Agreement on Design of SHIELD II PIII Trial Evaluating D-PLEX
22 May 2023 //
GLOBENEWSWIRE
PolyPid Provides Corporate Update and Reports 1Q 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
PolyPid to Report 1Q 2023 FYR and Operational Highlights on May 10, 2023
26 Apr 2023 //
GLOBENEWSWIRE
PolyPid to Participate in Upcoming Investor Conferences
24 Apr 2023 //
GLOBENEWSWIRE
PolyPid Announces Receipt of Nasdaq Notification
14 Apr 2023 //
GLOBENEWSWIRE
PolyPid Announces Closing of Underwritten Public Offering
31 Mar 2023 //
GLOBENEWSWIRE
PolyPid Announces Pricing of $6.2M Underwritten Public Offering of Shares
29 Mar 2023 //
GLOBENEWSWIRE
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
28 Mar 2023 //
GLOBENEWSWIRE
PolyPid to Present at the Barclays Global Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
PolyPid Reports Fourth Quarter and Full Year 2022 Financial Results
08 Feb 2023 //
GLOBENEWSWIRE
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results
31 Jan 2023 //
GLOBENEWSWIRE
PolyPid Provides Positive Regulatory Update for D-PLEX
24 Jan 2023 //
GLOBENEWSWIRE
PolyPid Announces Publication in the American Journal of Surgery of Ph2 Trial
03 Jan 2023 //
GLOBENEWSWIRE
PolyPid Announces Scheduling of Type D Meeting U.SFDA to Discuss SHIELD I P3
12 Dec 2022 //
GLOBENEWSWIRE
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
09 Dec 2022 //
GLOBENEWSWIRE
PolyPid to Report Third Quarter 2022 Financial Results
26 Oct 2022 //
GLOBENEWSWIRE
PolyPid Announces Cost Reduction Plan
20 Oct 2022 //
GLOBENEWSWIRE
PolyPid Announces Eligibility for European Medicines Agency Centralized
28 Sep 2022 //
GLOBENEWSWIRE
PolyPid Announces Peer-Reviewed Publication of Ph2 Trial Results for D-PLEX???
19 Sep 2022 //
GLOBENEWSWIRE
PolyPid Announces Presentation of Ph 2 D-PLEX??? Clinical at European Society
12 Sep 2022 //
GLOBENEWSWIRE
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX???
02 Sep 2022 //
GLOBENEWSWIRE
PolyPid Provides Corporate Update and Reports Q2 Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for D-PLEX???
03 Aug 2022 //
GLOBENEWSWIRE
PolyPid to Report Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
PolyPid Announces Presentation of PII D-PLEX Clinical Data at MSA 2022
25 Jul 2022 //
GLOBENEWSWIRE
PolyPid Hosting Key Opinion Leader Webinar for Cost of Surgical Site Infections
15 Jun 2022 //
GLOBENEWSWIRE
PolyPid Announces Presentation of D-PLEX‚PII Data at ASM Microbe 2022
06 Jun 2022 //
GLOBENEWSWIRE
